Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767)
10/2000
10/12/2000CA2366944A1 Pyrrolidine modulators of chemokine receptor activity
10/12/2000CA2365834A1 Herbal compositions and uses for the treatment of allergic reactions
10/12/2000CA2365421A1 Vesicle associated proteins
10/11/2000EP1043329A1 Crystal of diuridine tetraphosphate or salt thereof and method for preparing the same, and method for producing said compound
10/11/2000EP1042674A1 148 human secreted proteins
10/11/2000EP1042468A2 Low-voltage activated calcium channel compositions and methods
10/11/2000EP1042329A1 Novel farnesyl transferase inhibitors, preparation, pharmaceutical, compositions containing them and use for preparing medicines
10/11/2000EP1042319A1 Dihydrobenzofurans
10/11/2000EP1042300A1 Phthalazine derivatives phosphodiesterase 4 inhibitors
10/11/2000EP1042297A1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors
10/11/2000EP1042279A1 Substituted beta-alanines
10/11/2000EP1041990A1 Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
10/11/2000EP1041989A1 Novel cycloalkenyl substituted compounds
10/11/2000EP1041982A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
10/11/2000EP1041966A2 Pharmaceutical compositions
10/11/2000CN1269722A Method and composition for modulating responsiveness to corticosteroids
10/11/2000CN1269715A Method and composition for treating late allergic reactions and inflammation diseases
10/11/2000CN1057296C Morpholine and thiomorpholine tachykinin receptor antagonists and use
10/11/2000CN1057225C Process for preparing charantin
10/11/2000CN1057214C Cooling throat oral liquor and preparation technology
10/11/2000CN1057212C Oral liquor for body-building
10/10/2000US6130233 Methods and compositions for treating allergic disorders and other disorders using metabolic derivatives of astemizole
10/10/2000US6130226 Immunotherapeutic agents
10/10/2000US6129913 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
10/10/2000CA2147606C Stable extended release oral dosage composition
10/05/2000WO2000058512A1 Antisense modulation of interleukin-5 signal transduction
10/05/2000WO2000058495A1 45 human secreted proteins
10/05/2000WO2000058494A1 50 human secreted proteins
10/05/2000WO2000058475A2 Streptococcus pneumoniae antigens
10/05/2000WO2000058473A2 Nucleic acids including open reading frames encoding polypeptides; 'orfx'
10/05/2000WO2000058468A2 47 human secreted proteins
10/05/2000WO2000058467A1 50 human secreted proteins
10/05/2000WO2000058466A2 Protease resistant flint analogs
10/05/2000WO2000058465A2 Flint polypeptide analogs
10/05/2000WO2000058355A1 50 human secreted proteins
10/05/2000WO2000058348A1 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
10/05/2000WO2000058339A2 50 human secreted proteins
10/05/2000WO2000058334A1 50 human secreted proteins
10/05/2000WO2000058309A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one
10/05/2000WO2000058308A1 DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE
10/05/2000WO2000058307A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000WO2000058305A1 Novel compounds
10/05/2000WO2000058295A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
10/05/2000WO2000058292A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives
10/05/2000WO2000057920A2 Method for expressing proteins
10/05/2000WO2000057913A1 Preventives/remedies for interstitial pneumonia and pulmonary fibrosis
10/05/2000WO2000057903A2 48 human secreted proteins
10/05/2000WO2000057901A1 Modulation of vascular permeability by means of tie2 receptor activators
10/05/2000WO2000057897A1 Use of a lectin or conjugates for modulation of c-fibre activity
10/05/2000WO2000057890A1 Pulmonary delivery of protonated/acidified nucleic acids
10/05/2000WO2000057880A1 Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
10/05/2000WO2000057701A1 Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
10/05/2000WO2000031280A3 Use of plus-strand synthesis elements in retroviral vectors
10/05/2000WO2000029574A3 Inflammation-associated genes
10/05/2000WO2000026243A3 Transmembrane 4 proteins
10/05/2000WO1998041232A3 Compositions for modulating responsiveness to corticosteroids
10/05/2000DE10004860A1 Pressurized air inhaler for administering drug-containing liposomal powder aerosol for treatment of respiratory disease, has nebulization chamber for drying aqueous liposome suspension
10/05/2000CA2383592A1 2384891 acids including open reading frames encoding polypeptides; orfx
10/05/2000CA2369458A1 47 human secreted proteins
10/05/2000CA2368951A1 50 human secreted proteins
10/05/2000CA2368927A1 45 human secreted proteins
10/05/2000CA2368881A1 50 human secreted proteins
10/05/2000CA2368760A1 Flint polypeptide analogs
10/05/2000CA2368719A1 50 human secreted proteins
10/05/2000CA2368641A1 Use of a lectin or conjugates for modulation of c-fibre activity
10/05/2000CA2368467A1 50 human secreted proteins
10/05/2000CA2368460A1 Derivatives of pyrimido¬6,1-a|isoquinolin-4-one
10/05/2000CA2368442A1 48 human secreted proteins
10/05/2000CA2368281A1 50 human secreted proteins
10/05/2000CA2368090A1 Compounds and methods for treatment of asthma, allergy and inflammatory disorders
10/05/2000CA2367882A1 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
10/05/2000CA2366305A1 Method for expressing proteins
10/05/2000CA2365401A1 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands
10/05/2000CA2361366A1 Novel compounds
10/05/2000CA2359652A1 Novel prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of peripheral vascular disease and pulmonaryhypertension
10/04/2000EP1041072A1 Dioxocyclopentyl hydroxamic acids
10/04/2000EP1040838A1 Stable aqueous EM 12 solution
10/04/2000EP1040191A2 Rantes mutants and therapeutic applications thereof
10/04/2000EP1040190A1 Serine proteinase inhibitors
10/04/2000EP1040101A1 Substituted 2-aryl-4-amino-chinazolines, method for the production and use thereof as medicaments
10/04/2000EP1040100A1 Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
10/04/2000EP1040099A1 Azepine or larger medium ring derivatives and their use as pharmaceuticals
10/04/2000EP1040097A1 Potassium channel openers
10/04/2000EP1039935A1 USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
10/04/2000EP1039911A1 MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS
10/04/2000EP1039904A1 Synergistic antimicrobial compositions
10/04/2000EP1039903A1 Il-8 receptor antagonists
10/04/2000EP1039804A1 Method for treating fibroproliferative disorders by inhibitors of protein hydroxylation
10/04/2000EP1023279A4 Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
10/04/2000EP1019040A4 INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
10/04/2000EP0772610B1 Dihydrobenzofuranes
10/04/2000EP0699236B1 Purified mammalian flt3 ligands and agonists and antagonists thereof
10/04/2000CN1268938A Aminocycloalkane compounds
10/04/2000CN1057007C Application of theaflavine for preparing medicine for treating pulmonitis
10/04/2000CN1056974C Method for preparing drug material suitable for micronisation
10/03/2000US6127554 2,4-bis[(4-amidino)phenyl]furans as anti-Pneumocystis carinii agents
10/03/2000US6127542 Chemical intermediates to specified pyrazino(2',1':6,1)pyrido(3,4b)indole-1,4-diones which are selective inhibitors of cyclic guanosine 3',5'-monophosphate specific phosphodiesterase; to treat cardiovascular disorders
10/03/2000US6127423 Phenylamidine derivatives, a process for preparing the same and their use as medicaments
10/03/2000US6127408 Thioether furan nitrone compounds; nervous system degenerative disorders, e.g. alzheimer's disease; analysis of free radicals by forming adducts; inhibit the forming of a beta(1-42) beta-pleated sheets and/or suppressing cytokines
10/03/2000US6127401 Treatment of prostate disorders, angiogenic disorders, neoplasia, rheumatoid arthritis, pulmonary fibrosis, myelofibrosis, abnormal wound healing, atherosclerosis, or restenosis, alzheimer's disease